Dr. Neelapu on the Safety Profile of KTE-C19 in Patients With Lymphoma

Video

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

There were 2 common adverse events observed by researchers in the ZUMA-1 study, explains Neelapu. These include cytokine release syndrome (CRS) and neurological side effects. CRS typically manifests as body aches, fever, hypoxia, and a drop in blood pressure. The majority of CRS events were grades 1/2; 13% experienced grade 3/4 CRS, he adds.

Neurological events were of grade 1/2, including tremors, confusion, delirium, etc. Twenty-nine percent of patients had grade 3 or higher levels of neurological events. There were 2 treatment-related deaths that occurred on the study; 1 was from hemophagocytic lymphohistiocytosis, while the other was due to cardiac arrest in the setting of CRS. There was a third patient death caused by pulmonary embolism, but this was not related to KTE-C19, he says.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.